ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - Generic Drug Details

What are the generic sources for elexacaftor, ivacaftor, tezacaftor; ivacaftor and what is the scope of patent protection?

Elexacaftor, ivacaftor, tezacaftor; ivacaftor is the generic ingredient in one branded drug marketed by Vertex Pharms Inc and is included in two NDAs. There are thirty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Elexacaftor, ivacaftor, tezacaftor; ivacaftor has five hundred and eighteen patent family members in forty-eight countries.

One supplier is listed for this compound.

Summary for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

International Patents:	518
US Patents:	35
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	23
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
DailyMed Link:	ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Dosage:

TABLET, TABLET;ORAL

Dosage:

GRANULES;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vertex Pharmaceuticals Incorporated	PHASE3
University of Kansas Medical Center	PHASE2
Chiesi USA, Inc.	Phase 4

See all ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

R07AX	Other respiratory system products
R07A	OTHER RESPIRATORY SYSTEM PRODUCTS
R07	OTHER RESPIRATORY SYSTEM PRODUCTS
R	Respiratory system

US Patents and Regulatory Information for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-001	Apr 26, 2023		RX	Yes	No			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021		RX	Yes	No			Y	Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes			Y	Y

Expired US Patents for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-001	Apr 26, 2023
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023

International Patents for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Country	Patent Number	Title	Estimated Expiration
Mexico	366161
Hong Kong	1212672
South Korea	102336926
China	101384172
Lithuania	3219705

Supplementary Protection Certificates for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2826776	PA2021508	Lithuania		PRODUCT NAME: (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOKSOL-5-IL)-N-(1-(2,3-DIHIDROKSIPROPIL)-6-FLUOR-2-(1-HIDROKSI-2-METILPROPAN-2-IL)-1H-INDOL-5-IL) CIKLOPROPANKARBOKSAMIDO ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS IR (B) N-(5-HIDROKSI-2,4-DITERT-BUTIL-FENIL)-4-OKSO-1H-CHINOLIN-3-KARBOKSAMIDO ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS DERINYS; REGISTRATION NO/DATE: EU/1/18/1306 20181031
1773816	132016000022519	Italy		PRODUCT NAME: IVACAFTOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(KALYDECO); AUTHORISATION NUMBER(S) AND DATE(S): EU/12/782/001-002, 20120725
2826776	2190015-4	Sweden		PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2- METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1306, 2018-11-06; DEN 19 JUNI 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 1790034-1 1490061-7 1790019-2 2090047-8 2390009-5 2390012-9 2090033-8 1790016-8 2190015-4 1990020-8 1090038-9 1190029-7
1773816	237 5014-2015	Slovakia		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERC-BUTYL-FENYL)-4-OXO- -1H-CHINOLIN-3-KARBOXAMID (IVACAFTOR); REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120725
1773816	SPC/GB15/041	United Kingdom		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/782/001 20120725; UK EU/1/12/782/002 20120725

Market Dynamics and Financial Trajectory for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR: A Comprehensive Analysis

Last updated: January 16, 2026

Executive Summary

The pharmaceutical landscape surrounding cystic fibrosis (CF) therapies has experienced significant transformation with the advent of CFTR modulators, notably the combination therapies involving Elexacaftor, Ivacaftor, and Tezacaftor. These targeted treatments have shifted the paradigm from symptomatic management to disease-modifying options, fundamentally altering market dynamics and forecasted revenues.

Elexacaftor, Ivacaftor, and Tezacaftor—collectively branded as Trikafta (or Kaftrio, depending on regional branding)—have demonstrated robust clinical efficacy, rapid adoption, and expanding indications that underpin a compelling financial trajectory. This report delves into the current market landscape, projected growth, competitive environment, key drivers, challenges, and strategic considerations for stakeholders.

---

What Are the Core Components and Mechanisms of Elexacaftor, Ivacaftor, and Tezacaftor?

Component	Function	Mechanism of Action	Indication	Regulatory Status
Elexacaftor	Corrects CFTR misfolding	Enhances trafficking of F508del CFTR to the cell surface	CF patients with F508del mutation	Approved in US (2019), EMA (2020)
Ivacaftor	Potentiator of CFTR channel opening	Improves gating function	Multiple mutations, including G551D	Approved globally, first CFTR modulator (2012)
Tezacaftor	Corrects CFTR folding	Assists in maturation and trafficking	CF with certain mutations; replaced by Elexacaftor in triple therapy	Approved in combination with Ivacaftor (2018)

Note: The triple combination (Elexacaftor + Tezacaftor + Ivacaftor) exhibits synergistic effects, markedly improving lung function and quality of life.

---

Current Market Landscape

Key Players and Approvals

Company	Drug(s)	Approval Dates	Market Share	Notes
Vertex Pharmaceuticals	Elexacaftor + Tezacaftor + Ivacaftor (Trikafta/Kaftrio)	US (2019), EU (2020)	Dominant	Leader in CFTR modulator market
AbbVie / Roche	Investigational variants	N/A	N/A	Potential competitors in pipeline

Major Markets:

• United States
• European Union
• Canada
• Japan
• Australia

Market Size (2022): Estimated at $4.5 billion globally, primarily driven by the US and EU markets.

---

Market Drivers

Driver	Impact	Details
Unmet Medical Need	High	CF affects ~70,000 individuals worldwide; limited efficacy of earlier therapies
Regulatory Approvals	Accelerated	Rapid approvals following robust Phase III data (e.g., Vertex’s Trikafta)
Clinical Efficacy	Strong	Median FEV1 improvements (~14-15%), increased life expectancy
Pricing Strategies	High Revenue	List prices range from $300,000 to $325,000 annually per patient in the US
Expanding Indications	Growth Potential	Use in broader CF genotypes and age groups, including pediatric populations

Market Challenges

Challenge	Impact	Details
High Cost	Barrier	Insurance coverage and reimbursement issues in some regions
Competitive Landscape	Growing	Potential entrants and biosimilar developments
Pricing Pressure	Risk	Payers seeking cost reductions; value-based reimbursement models
Patient Access	Variability	Disparities in healthcare infrastructure

---

Financial Trajectory: Revenue Forecast and Growth Drivers

Historical Revenue Performance

Year	Revenue (USD Billion)	Comments
2019	N/A	Approximate initial US launch, limited global access
2020	~$3.3 billion	Rapid growth following US approval of Trikafta
2021	~$4.0 billion	Expansion into new markets; increased adoption
2022	~$4.5 billion	Continued penetration; introduction in pediatric populations

Note: The data reflects reported revenues primarily from Vertex Pharmaceuticals.

Forecasted Revenue (2023–2027)

Year	Projected Revenue (USD Billion)	Growth Rate	Assumptions
2023	$5.2	15.5%	Fuller global access, expanded indications
2024	$6.0	15.4%	Launch in additional markets, pediatric approval
2025	$6.8	13.3%	Increasing penetration, biosimilar competitors' entrance
2026	$7.5	10.3%	Market saturation, pricing pressures
2027	$8.2	9.3%	Sustained growth through pipeline expansion

Source: Industry estimates, Vertex’s guidance, and market trends.

Revenue Drivers

• Broadened Approvals: Expanded indications in children aged 6-11; potential approvals for even younger children.
• Global Market Penetration: Increasing adoption in emerging markets with negotiated pricing.
• New Formulations: Long-acting variants and combination formulations enhancing adherence.
• Pipeline Product Introductions: Next-generation modulators and combination strategies.

---

Competitive and Strategic Considerations

Main Competitors and Pipeline Landscape

Company	Drug(s)	Development Stage	Target Mutations	Distinctive Features
Vertex	Next-gen CFTR modulators	Ongoing	Broader mutation coverage	Potential to extend patent life and maintain market dominance
ProQR	QR-421a (RNA therapy)	Phase II	Nonsense mutations	Alternative modality addressing unmet needs
Mitsubishi Tanabe	Kaftrio variants	Submitted	F508del and others	Regional competition in Asia

Strategic Opportunities

• Pricing Strategy Optimization: Navigating reimbursement policies to sustain revenue growth.
• Pipeline Expansion: Investing in next-generation CFTR modulators, gene editing, and RNA therapies.
• Regional Market Penetration: Focused expansion in Asia-Pacific and Latin America.
• Partnerships & Licensing: Collaborations with biotech firms for innovation.

---

Regulatory Policies and Reimbursement Environment

Region	Reimbursement Policy	Key Notes	Impact on Market Dynamics
US	Medicaid, Medicare, Commercial	Value-based negotiations emerging	High prices justified by clinical benefits; payer resistance remains
EU	National health authorities	Cost-effectiveness evaluations	Price negotiations and discounts vary; some countries limit reimbursement
Japan	National health insurance	Focused on cost-efficiency	Negotiated pricing, potential delays in approval

The evolving reimbursement landscape influences market access and shapes the revenue trajectory.

---

Market Outlook: Opportunities and Risks

Opportunities	Risks
Expanded indications in pediatric populations	Pricing pressures and cost-containment policies
Emerging markets adoption	Potential biosimilar entrants
Pipeline innovation	Regulatory hurdles for new therapies
Combination with gene therapy approaches	Market saturation in core demographics

---

Key Takeaways

• Elexacaftor, Ivacaftor, and Tezacaftor form the backbone of current CFTR modulator therapies, with a market-leading position driven by high efficacy and expanding indications.
• Revenue projections indicate sustained growth, averaging approximately 10–15% annually through 2027, primarily driven by global expansion and pediatric approvals.
• Pricing strategies remain pivotal; high drug costs are offset by demonstrable clinical benefits, but payer pushback may challenge growth.
• Pipeline developments and next-generation modulators could extend patent exclusivity and introduce new revenue streams.
• Market competition remains moderate but increasing, with potential biosimilar entries and alternative modalities shaping the future landscape.

---

Frequently Asked Questions

1. What are the differentiators of Elexacaftor, Ivacaftor, and Tezacaftor compared to earlier CF treatments?
They target the underlying CFTR protein defect, offering substantial improvements in lung function and quality of life, unlike previous symptomatic therapies such as dornase alfa or inhaled antibiotics.

2. How does the pricing of these drugs impact market adoption?
High annual costs (~$300,000–$325,000 per patient) pose reimbursement challenges, but widespread insurance coverage and proven efficacy justify premium pricing, especially in well-funded healthcare systems.

3. What is the potential for biosimilars or generic versions in this market?
Given the high R&D costs and patent protections, biosimilars may enter markets post-patent expiry (likely after 2030), but complex biologic manufacturing and regulatory pathways could delay entry.

4. Are there notable regional disparities in access?
Yes. Markets like the US and Europe benefit from established reimbursement, whereas emerging markets face affordability and infrastructure barriers, influencing global revenue distribution.

5. What pipeline innovations could influence future market dynamics?
Next-generation modulators, gene editing technologies (e.g., CRISPR), and RNA-based therapies hold promise to broaden treatment options and potentially replace current modulators.

---

References

1. Vertex Pharmaceuticals. (2022). Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) Product Label.
2. EMA. (2020). Approval summaries for CFTR modulators.
3. FDA. (2019). Biologics License Application for Trikafta.
4. Market Research Future. (2022). Global Cystic Fibrosis Market Analysis.
5. ICER. (2021). Assessment of CFTR Modulators' Cost-Effectiveness.